Cassava Sciences Reveals Promising Simufilam Preclinical Data
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Cassava Sciences ( (SAVA) ).
On June 30, 2025, Cassava Sciences announced promising preclinical data for simufilam, presented at the TSC International Research Conference. The data demonstrated that simufilam reduced seizure activity by 60% in a preclinical mouse model of TSC-related epilepsy, and showed a favorable safety profile in human Phase 3 studies for Alzheimer’s disease. This supports Cassava’s plan to initiate human clinical trials for TSC-related epilepsy in the first half of 2026, potentially impacting treatment options for the approximately 50,000 patients in the US living with this rare disease.
The most recent analyst rating on (SAVA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing novel, investigational treatments for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy. Their primary product under development is simufilam, a proprietary oral small molecule hypothesized to modulate the function of the filamin A protein.
Average Trading Volume: 1,127,975
Technical Sentiment Signal: Sell
Current Market Cap: $84.54M
See more data about SAVA stock on TipRanks’ Stock Analysis page.
